Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?
نویسندگان
چکیده
Abstract Purpose: With the rising incidence of early-onset pancreatic cancer (EOPC), molecular characteristics that distinguish ductal adenocarcinoma (PDAC) tumors from those arising at a later age are not well understood. Experimental Design: We performed bioinformatic analysis genomic and transcriptomic data generated 269 advanced (metastatic or locally advanced) 277 resectable PDAC tumor samples. Patient samples were stratified into EOPC (age onset ≤55 years; n = 117), intermediate 55–70 264), average ≥70 165) groups. Frequency somatic mutations affecting genes commonly implicated in PDAC, as gene expression patterns, compared between all other Results: showed significantly lower frequency single-nucleotide variant (SNV)/insertions/deletions (indel) CDKN2A (P 0.0017), more likely to achieve biallelic mutation through homozygous copy loss opposed heterozygous coupled with loss-of-function SNV/indel mutation, latter which was common for ages 1.5e-4). Transcription factor forkhead box protein C2 (FOXC2) upregulated 0.032). Genes correlated FOXC2 enriched sets related epithelial-to-mesenchymal transition (EMT) included VIM 1.8e-8), CDH11 6.5e-5), CDH2 2.4e-2). Conclusions: Our comprehensive sequencing large cohort patient highlights distinctive pattern tumors. Increased EOPC, correlation EMT pathways, represents novel EOPC. See commentary by Lou, p. 8
منابع مشابه
Pancreatic ductal adenocarcinoma staging
In addition to clinical history and evaluations, the results of laboratory tests and imaging studies help clinicians in determining treatment strategies. Imaging plays a central role in the management of oncology patients including the initial diagnosis, staging, and follow-up to assess treatment response. Historically, radiologists have relied on free-style dictations to convey the results of ...
متن کاملPancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas. PDAC is an aggressive and difficult malignancy to treat. Complete surgical removal of the tumor remains the only chance for cure, however 80-90% of patients have disease that is surgically incurable at the time of clinical presentation (15). Despite our advancing knowledge of the tumor biology of PDAC, improv...
متن کاملPancreatic ductal adenocarcinoma: long-term survival does not equal cure.
BACKGROUND Pancreatic ductal adenocarcinoma represents 90% of pancreatic cancers and is an important cause of cancer death in the United States. Operative resection remains as the only treatment providing prolonged survival, but even after a curative resection, 5-year survival rates are low. Our aim was to identify the prognostic factors for long-term survival after resection of pancreatic duct...
متن کاملPrognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
The outcomes of patients treated with surgery for early stage pancreatic ductal adenocarcinoma (PDAC) are variable with median survival ranging from 6 months to more than 5 years. This challenge underscores an unmet need for developing personalized medicine strategies to refine the current treatment decision-making process. To derive a prognostic gene signature for patients with early stage PDA...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2021
ISSN: ['1557-3265', '1078-0432']
DOI: https://doi.org/10.1158/1078-0432.ccr-20-1042